Evolus (EOLS) Stock Forecast & Price Target

Evolus is benefiting from resilient demand in the cash-pay aesthetic market, with 2Q26 revenue rising 21.2% year over year to $84.1M, 600 new customer accounts added, and a ~70% reorder rate that signals durable product loyalty. Its outlook is further strengthened by Jeuveau’s 14% U.S. market share, Evolysse’s early traction across about 3,500 accounts, and the potential of Sculpt to deepen account penetration once FDA approval arrives in 4Q26. Management’s ability to raise FY26 revenue guidance to $330M-$337M, deliver two consecutive quarters of positive adjusted EBITDA, and maintain 69.0% adjusted gross margin supports a credible path toward scalable profitability and portfolio leverage.

Evolus is exposed to a challenging cash-pay aesthetic market where demand can weaken if consumer spending deteriorates, making its growth more cyclical and vulnerable than companies with recurring reimbursement-driven revenue. The outlook is further pressured by execution risk across its commercial launch, including a slower-than-expected ramp of Evolysse, supply chain challenges, potential tariffs, regulatory delays, and negative clinical data updates, any of which could limit adoption and delay revenue diversification beyond Jeuveau. Competition, pricing pressure, and higher-than-expected operating expenses add another layer of fundamental risk by squeezing margins and making it harder for the company to translate its U.S., Canada, Europe, and Australia footprint into consistent profitability.